Business
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from Internatio...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: RIGHT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen3{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnbcc{\nBORDER-TOP:0pt solid; BORDER-RIGHT:0pt solid; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt solid; BORDER-LEFT:0pt solid\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n \n Vascepa included in Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology\n \n 1\n \n \n \n \n \n \n \n \n \n \n \n Chinese Society of Cardiology updated Guidelines now include Vascepa in its Prevention of Cardiovascular Diseases\n \n \n \n \n \n \n \n \n \n \n Vascepa is now included in the treatment guidelines or otherwise recommended for use by 13 medical associations worldwide including Thrombosis Canada\n \n 2-14\n \n \n \n \n \n \n \n HLS expects the Canadian Cardiovascular Society will review and potentially update its lipid management guidelines in 2021\n \n \n \n \n \n \n TORONTO\n \n ,\n \n Jan. 28, 2021\n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces new support from independent medical societies for the use of Vascepa (icosapent ethyl) in reducing the risk of a Major Adverse Cardiovascular Event (MACE).\n \n \n In the recent\n \n Consensus Statement by the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm\n \n 2020 executive summary\n \n 1\n \n , the AACE treatment algorithm r...